article thumbnail

London’s life sciences scene upbeat as 2024 conference season begins

pharmaphorum

London's burgeoning life sciences scene is kicking off 2024 with optimism as the city prepares to host major conferences like Anglonordic. Discover how antibody discovery biotechs like Alchemab are driving growth and innovation in the sector.

article thumbnail

Tiziana Life Sciences plans to assess intranasal foralumab for long Covid

Pharmaceutical Technology

Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Foralumab is a fully human anti-CD3 monoclonal antibody, which works by binding to the T-cell receptor and regulating T-cell function to reduce pulmonary inflammation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK boosts life science innovation with £277 million funding

Pharmaceutical Technology

On March 28, the UK government announced that four UK life sciences companies will receive £277 million to help fund and advance manufacturing projects in medical diagnostics and human medicines. This is the first big spend being made from the UK’s Life Sciences Innovative Manufacturing Fund (LSIMF).

article thumbnail

Developing Conditionally Active Antibodies Targeting the Tumor Microenvironment ft. John K. Celebi, CEO, Sensei Bio – Xtalks Life Science Podcast Ep. 156

XTalks

Sensei Biotherapeutics specializes in creating conditionally active antibodies engineered to operate specifically within the acidic tumor microenvironment, enhancing the immune system’s ability to combat cancer. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

Biologics Development in Immunology and Inflammation — Featuring Amir Reichman, CEO of Scinai Immunotherapeutics – Xtalks Life Science Podcast Ep. 147

XTalks

Scinai Immunotherapeutics is working on developing nanosized antibodies from alpacas, known as VHH-antibodies or NanoAbs, which show promise as improved biological therapies for various illnesses. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

Novel Approaches in Cancer Immunotherapy — Featuring OncoC4 founder, CEO and CSO Dr. Yang Liu and CFO Abid Ansari – Xtalks Life Science Podcast Ep. 146

XTalks

This includes first-in-class immunotherapy products such as novel antibodies and CAR T-cell treatments targeting CTLA-4. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. OncoC4 is a spinout of OncoImmune, which was acquired by Merck in December 2020.

article thumbnail

Sanofi announces €300m collaboration with Blackstone Life Sciences for multiple myeloma treatment

BioPharma Reporter

Sanofi and Blackstone today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to â300m ($329m) to accelerate development for subcutaneous formulation and delivery of anti-CD38 antibody Sarclisa to treat patients with multiple myeloma (MM).